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Abstract 
Background: The pathogenesis of malaria is primarily associated with blood-stage infection and there is strong 
evidence that antibodies specific for parasite blood-stage antigens can control parasitaemia. This provides a strong 
rationale for incorporation of asexual blood-stage antigen components into an effective multivalent malaria subu-
nit vaccine. On the basis of available genome-wide transcriptomic and proteomic data, previously uncharacterized 
Plasmodium falciparum open reading frames were screened for new blood stage vaccine candidates. This has led to 
the identification of the cysteine-rich protective antigen (PfCyRPA), which forms together with PfRH5 and PfRipr a 
multiprotein complex that is crucial for erythrocyte invasion.
Methods: Glycosylated and non-glycosylated variants of recombinant PfCyRPA were expressed and produced as 
secreted protein in mammalian cells. Adjuvanted formulations of purified PfCyRPA were tested to assess whether they 
can effectively elicit parasite inhibitory antibodies, and to investigate whether or not the glycosylation status affects 
antibody binding. For this purpose, two sets of PfCyRPA-specific mouse monoclonal antibodies (mAbs) have been 
raised and evaluated for functional activity.
Results: Generated PfCyRPA-specific mAbs, irrespective of the immunogen’s glycosylation status, showed substantial 
parasite in vitro growth-inhibitory activity due to inhibition of erythrocyte invasion by merozoites. Furthermore, pas-
sive immunization experiments in P. falciparum infected NOD-scid IL2Rγnull mice engrafted with human erythrocytes 
demonstrated potent in vivo growth-inhibitory activity of generated mAbs.
Conclusions: Recombinantly expressed PfCyRPA tested as adjuvanted vaccine formulations in mice elicited antibod-
ies that significantly inhibit P. falciparum asexual blood stage parasite growth both in vitro and in vivo. These findings 
render PfCyRPA a promising blood-stage candidate antigen for inclusion into a multicomponent malaria subunit 
vaccine.
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Background
The World malaria report 2015 reported the reduction 
of malaria mortality rates by an impressive 48 % between 
2000 and 2015 as a result of a major scale-up of vector 
control interventions, diagnostic testing, and treatment 
with artemisinin‐based combination therapy [1]. Despite 
these tremendous achievements, an estimated 214 mil-
lion cases of malaria occurred globally in 2015, and 
the disease led to 438,000 deaths, mostly those of chil-
dren under 5 years of age in Africa [1]. Limited efficacy 
achieved by subunit vaccine candidates, emerging anti-
malarial drug resistances, along with reported insecticide 
resistances, underline the need of new tools to control 
and prevent malaria [2, 3]. In this perspective, the devel-
opment of an effective malaria vaccine is recognized as 
one of the most promising approaches to conquer the 
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disease. Despite decades of research, an effective vaccine 
against malaria has remained elusive. Anti-malarial vac-
cines can break the parasite life cycle at different stages: 
infection-blocking vaccines targeting hepatic stages, anti-
morbidity vaccines targeting the asexual blood stages, 
and transmission-blocking vaccines targeting the sexual 
stages. To achieve effective protection, the ideal malaria 
vaccine is thought to target several steps of the parasite 
life-cycle in a multistage combination vaccine [4].
Clinical and experimental data support the feasibility 
of developing an effective malaria vaccine. Adults liv-
ing in malaria endemic areas rarely experience malaria 
episodes: partial protection of adults is mediated by 
naturally acquired immunity, and protects against symp-
tomatic disease and high‐density parasitaemia, but is 
not effective in offering sterile immunity [5]. Also, pas-
sive transfer of γ-globulin from semi-immune adults to 
malaria patients conferred a significant reduction of par-
asitaemia and recovery from clinical symptoms [6]. Those 
studies showed that immunity can be naturally acquired 
with exposure and indicated antibodies as crucial com-
ponents of the protective immune response against 
asexual blood stage parasites. In this perspective, a multi-
stage malaria vaccine should contain as one component 
antigen(s) that elicit antibody responses upon parasite 
presentation, leading to clearance of asexual blood stage 
parasites, and thus reducing the clinical symptoms.
Currently, with a total 25 projects in the pipeline 
[7], three candidate vaccines are in phase 2B clini-
cal trials and one, the pre-erythrocytic subunit vaccine 
RTS,S/AS01, has completed phase 3 [8]. In infants aged 
6–12 weeks at first vaccination with four doses of RTS,S 
reduced the number of cases of clinical malaria by 26 % 
to the end of the study over an follow-up of 38 months. 
Blood-stage vaccines, designed to elicit anti-invasion and 
anti-disease responses [9], are traditionally mainly based 
on a few protein candidate antigens: apical membrane 
antigen 1 (AMA1) [10–12], erythrocyte-binding anti-
gen-175 (EBA-175) [13], glutamate-rich protein (GLURP) 
[14, 15], merozoite surface protein (MSP) 1 [16], MSP2 
[17, 18] and MSP3 [19, 20] and serine repeat antigen 5 
(SERA5) [21, 22]. These immunodominant antigens, 
highly expressed on merozoites surface or within api-
cal organelles, are involved in the invasion process. 
Unfortunately, AMA1 and MSP1, the most advanced 
blood-stage vaccines, have not demonstrated effective 
protection in African children [10, 16, 23], probably due 
to their highly polymorphic nature [24]. Genetic variabil-
ity, extensive polymorphism and antigenic complexity in 
immunodominant antigens represent major obstacles in 
the development of an effective blood-stage malaria vac-
cine [25–27]. Identifying and designing antigens able to 
induce strain-transcending immune responses, which 
cover antigenic diversity remains a critical issue to be 
addressed. Since the Plasmodium falciparum genome 
was sequenced and annotated in 2002 [28], reverse vac-
cinology represents the most attractive strategy to ration-
ally identify novel malaria vaccine candidates [29, 30]. On 
the basis of the large-scale genomic, transcriptomic, pro-
teomic and comparative data from Plasmodium spp. that 
have become available, new antigens with great potential 
as blood-stage vaccine candidates have been discovered 
[31].
Among the newly characterized proteins, the cysteine 
rich protective antigen (PfCyRPA) exhibited remark-
able properties: PfCyRPA (1) elicits Abs that inhibit 
parasite growth in  vitro and in  vivo [32], (2) is highly 
conserved among P. falciparum isolates [32], (3) has 
limited natural immunogenicity, and (4) forms together 
with the reticulocyte-binding homolog 5 (PfRH5) and the 
PfRH5-interacting protein (PfRipr) a multiprotein com-
plex crucial for P. falciparum erythrocyte invasion [33]. 
PfRH5 is currently regarded another leading blood-stage 
malaria vaccine candidate: it has been shown to induce 
invasion-inhibitory antibodies that are effective across 
common PfRH5 genetic variants and PfRH5-based vac-
cines can protect Aotus monkeys against virulent vac-
cine-heterologous P. falciparum challenges [34–37]. The 
PfCyRPA encoding gene PFD1130w is located in the 
subtelomeric region of chromosome 4 in close proximity 
to other genes playing a crucial role in the erythrocytes 
invasion, including PFD1145c that encodes for PfRH5 
[36]. PfCyRPA is a 362-aa-long protein with a predicted 
molecular mass of 42.8  kDa, an N-terminal signal pep-
tide, a C-terminal GPI-anchor motif and twelve cysteine 
residues, potentially involved in the formation of six 
disulfide bridges. PfCyRPA was identified as a promis-
ing blood-stage malaria vaccine candidate exploiting a 
cell-based approach that utilizes antigens expressed on 
the surface of mammalian cells for mouse immuniza-
tion [38]. Since antigen-loaded cells are not suitable for 
human immunization, the study investigated whether 
invasion inhibitory anti-PfCyRPA antibodies could be 
raised by active immunization with purified recombinant 
PfCyRPA protein. In the present study, PfCyRPA was 
recombinantly-expressed in mammalian cells and adju-
vanted vaccine formulations of purified PfCyRPA were 
tested for their potential to elicit antibodies that inhibit P. 
falciparum parasite growth in vitro and in vivo.
Methods
Bacterial strains and media
Escherichia coli strain Top10 (Life Technologies) was 
used for the amplification of plasmids. Bacteria were 
grown in LB medium containing 100 μg/ml ampicillin at 
37 °C.
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Construction of expression plasmids
The expression vector which allows for the secretion of 
the recombinant PfCyRPA protein (aa 22–362) was gen-
erated by PCR-based mutagenesis [39–42] using the 
BVM_PFD1130W_FLAG_GP_His plasmid as template 
[38]. Briefly, a PCR product encompassing the bee-
venom melittin secretion signal (BVM) and PfCyRPA 
aa 26–352 codon-optimized sequence, was amplified 
using GeneAmp® High Fidelity PCR System (Life Tech-
nologies) and primer 4325 (5′-CAACTCCGCCCC 
ATTGACGCA-3′) and 4326 (5′-GGTGTGGATGTT 
GTAAATGCCCTGGGA-3′). The hexa-his tag was 
amplified with primers 4329 (5′-GAGGAATTCCATC 
ACCATCACCATCACTGATAA-3′) and 4330 (5′-AGG 
GCGATGGCCCACTACGT-3′). A double-stranded 
oligonucleotide encoding for PfCyRPA aa 353–362 
was generated by oligos-annealing employing the com-
plementary oligonucleotides 4327 (5′-ATTTACA 
ACATCCACACCATCTACTACGCCAACTACGAG 
GAATTCCATCACCAT-3′) and 4328 (5′-ATGGTGATG 
GAATTCCTCGTAGTTGGCGTAGTAGATGGTGTGG 
ATGTTGTAAAT-3′). In a second step, a ligation PCR 
was performed with the outermost primer pair (4325 
and 4330) using a mixture of the three previously gen-
erated PCR amplicons. Eventually, the recombined PCR 
product was recloned by NheI and XhoI (New Eng-
land Biolabs) resulting in plasmid pcDNA3.1_BVM_
CyRPA(26–362)_6xHis. This expression vector allows 
the expression of PfCyRPA with a hexa-His tag as 
secreted protein via the BVM signal peptide (designated 
G-CyRPA). It contains the secretion signal of bee-venom 
melittin, the coding sequence of the protein of interest 
and a hexa-His tag.
The expression vector coding for the non-glyco-
sylated PfCyRPA (N-CyRPA) was generated by site-
directed mutagenesis (GenScript) resulting in the 
expression plasmid pcDNA3.1_BMV_CyRPA(26–362/
N145Q-N322Q-N338Q)_6xHis.
Culture of eukaryotic cells
FreeStyle 293-F cells (Thermo Fisher), a variant of human 
embryonic kidney cell line HEK cells, were cultured 
in suspension in serum-free medium (FreeStyle™ 293 
Expression Medium, Thermo Fisher) at 37 °C in a humid-
ified incubator with 5 % CO2. Shake flask cultures were 
run in 1 l shake flasks (Corning, 120 rpm, 5 cm diameter) 
and 10  l cultures were performed in fully instrumented 
Wave bioreactors (Sartorius, Melsungen) under con-
trolled conditions (30 rpm, pH 7.2, 30 % DO).
Recombinant protein expression and purification
FreeStyle 293-F cells were transfected with pcDNA3.1_ 
BVM_CyRPA(26–362)_6xHis and pcDNA3.1_BMV_ 
CyRPA(26–362/N145Q-N322Q-N338Q)_6xHis plasmids 
using a riDOM-based transfection system [43]. Prior to 
transfection at 1.2 ×  106 cells/ml, cells were diluted 1:2 
with fresh culture medium and transfected with 0.4 mg/l 
expression plasmids and transfection reagents. Cell 
supernatants containing secreted proteins were typically 
harvested 72–96  h post-transfection. Histidine-tagged 
proteins were purified by immobilized metal ion affinity 
chromatography (IMAC). The purity and integrity of the 
purified proteins were analysed by RP-HPLC on an Agi-
lent 1290 Series with a Poroshell 300SB-C8, 1 × 75 mm 
column (Agilent). Chromatography was performed with 
a non-linear (H2O +  0.01 % TFA/Acetonitrile +  0.08 % 
TFA) gradient system. The protein concentration was 
determined by measuring the OD280 (1 Abs = 1 mg/ml). 
The purified recombinant proteins were identified as the 
expected G-CyRPA and N-CyRPA proteins by western 
blot analysis with PfCyRPA-specific mAbs [32].
Expression of PfCyRPA fragments on the surface of HEK 
cells
293 HEK cells expressing PfCyRPA fragments on the cell 
surface were generated essentially as described previously 
by Dreyer et al. [32]. Briefly, DNA sequences coding for 
the fragments of PfCyRPA were amplified by PCR from a 
plasmid containing the full length and codon-optimized 
sequence of PfCyRPA. The amplicons were digested with 
restriction endonucleases NheI and NotI (New England 
Biolabs) and then ligated into a pcDNA3.1-based expres-
sion vector [38]. This expression vector allows to anchor 
the protein of interest on the cell surface via the trans-
membrane domain of mouse glycophorin-A. In addition 
it contains the secretion signal of bee-venom melittin, 
a FLAG tag located extracellularly, and a hexa-His tag 
located in the cytosol. The 293 HEK cells were trans-
fected with the different expression vectors using JetPEI 
transfection reagent (PolyPlus) according to the manu-
facturer’s instructions. Transient transfectants were har-
vested 48 h post-transfection; cell lysates were generated 
as described below and used for Western blot analysis.
Immunization of mice
All procedures involving living animals were performed 
in strict accordance with the rules and regulations for 
the protection of animal rights (Tierschutzverordnung) 
of the Swiss Federal Food Safety and Veterinary Office. 
The protocol was granted ethical approval by the Vet-
erinary Office of the county of Basel-Stadt, Switzerland 
(Permit numbers: 2375 and 2303). Specific pathogen-
free HsdWin:NMRI outbred mice were purchased from 
Harlan Laboratories B.V. (The Netherlands) and used for 
immunizations studies. Sixteen mice were immunized 
intraperitoneally with 20  μg/injection of recombinant 
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protein emulsified in aluminum hydroxide gel (Alhy-
drogel-2  %, Brenntag Biosector) containing CpG ODN 
as immune enhancer [44]. The animals received three 
booster injections at 2  weeks intervals with the same 
antigen preparation. Two weeks after the last boost, 
blood was collected and the serum was tested for the 
presence of PfCyRPA-specific antibodies by ELISA and 
western blot analysis.
Fusion and cell‑based selection
The best immune responders were selected for fusion. 
These mice received an intravenous (i.v.) injection of 
20  μg of antigen dissolved in PBS 2  days before the 
fusion. Mice were sacrificed and the spleen was removed. 
Splenocytes were fused to the myeloma cell partner 
(PAI mouse myeloma cells, derived from SP-20, Insti-
tute of Immunology, Basel) using polyethylene glycol 
1500 (Roche Diagnostics). The fusion mix was plated 
into 96-well culture plates and hybridomas were selected 
by growing in HAT-medium supplemented with cul-
ture supernatant of mouse macrophages P388. Wells 
were screened for IgG production 2  weeks post-fusion 
by ELISA as described previously [38]. IgG-producing 
hybrids were further screened for PfCyRPA-specific IgG 
production by ELISA on recombinant PfCyRPA. Positive 
wells were cloned in HT-medium by limiting dilution to 
obtain monoclonal populations.
Antibody production and characterization
Identification of antibody subclasses was performed 
using a Mouse Monoclonal Antibody Isotyping Kit 
(ISO2, Sigma). For large-scale mAb production hybri-
doma cell lines were cultured in 500  ml roller-bottles 
(Corning). Monoclonal antibodies were purified by 
affinity chromatography using protein A sepharose (GE 
Healthcare).
Plasmodium falciparum blood stage culture
Plasmodium falciparum strain 3D7 was cultured essen-
tially as described previously [45]. The culture medium 
was supplemented with 0.5 % AlbuMAX (Life Technolo-
gies) as a substitute for human serum [46]. Cultures were 
synchronized by sorbitol treatment [47]. Erythrocytes 
for passages were obtained from the Swiss Red Cross 
(Switzerland). Plasmodium falciparum merozoites were 
mechanically released from mature schizonts as previ-
ously described [48]. Briefly, late-stage parasites (40–46 h 
post-invasion) were purified by Percoll density gradient 
[49] and incubated with 10  μM E-64 inhibitor (Sigma). 
After 6–8  h incubation, mature schizonts were filtered 
through 1.2  μm filters to release merozoites mechani-
cally. Then, merozoites were resuspended PBS and stored 
at −80 °C until further use.
ELISA
Detection of PfCyRPA‑specific Abs in mouse sera by ELISA
ELISA Maxisorp plates (Nunc) were coated with 10 μg/
ml purified recombinant G-CyRPA or MUL_3720 [50] 
proteins. After blocking, plates were incubated with dilu-
tions of mouse serum. Horseradish Peroxidase (HRP) 
conjugated goat anti-mouse γ-chain specific (Southern-
Biotech) was used as secondary antibody and tetrameth-
ylbenzidine substrate was used as substrate (KPL). The 
reaction was stopped with 0.5 M H2SO4 and the absorb-
ance at 450 nm was measured using the Sunrise Absorb-
ance Reader (Tecan). The cut-off value for calculation 
of endpoints titers was defined for each immunization 
group as:
Serum IgG endpoint titers were calculated as recipro-
cal values of the last dilution factor yielding an OD value 
higher than the cut-off. Data were processed and ana-
lysed using GraphPad Prism 6.0 (GraphPad).
Ab competition ELISA
Plates were coated with 10  μg/ml purified recombinant 
G-CyRPA protein; after blocking, plates were incubated 
with 10, 1, or 0  μg/ml of different anti-PfCyRPA mAbs. 
After 30 min, different biotinylated anti-PfCyRPA mAbs 
were added to each well resulting in a concentration of 
1 μg/ml of labelled mAb. As the two antibodies compete 
for the same binding site, the signal is reduced because 
less biotinylated detection antibody is able to bind to 
PfCyRPA. Alkaline phosphatase-conjugated streptavi-
din (Southern Biotech) was used as detecting agent, and 
p-nitrophenyl phosphate substrate (Sigma) was used for 
development. The OD of the reaction product was meas-
ured at 405  nm. Anti-PfCyRPA antibodies with a signal 
reduction higher than 30 % (compared to the absence of 
competitor) were considered as competing.
Western blotting analysis
Blood stage parasite lysates were prepared essentially 
as described previously by saponin lysis of P. falcipa-
rum 3D7-infected erythrocytes [45]. In brief, cultured 
parasites were washed once with PBS. Pelleted infected 
red blood cells were lysed in 20 volumes of 0.06 % (w/v) 
saponin in PBS and incubated on ice for 20  min. Para-
sites were washed and the final pellet was resuspended in 
three volumes of PBS and stored at −80 °C until further 
use. RIPA-lysates were prepared by resuspending sapo-
nin pellets in three volumes of complete lysis buffer (1 % 
NP40, 0.25 % DOC, 10 % glycerol, 2 mM EDTA, 137 mM 
NaCl, 20  mM Tris HCl pH 8.0, protease inhibitors) for 
10 min on ice. The lysates were cleared by centrifugation 
Average OD value
+ (2× Standard Deviation control)
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at 15,000g for 10 min and the supernatant kept at −80 °C 
until use. HEK cell lysate were prepared at 107 cells/ml 
in Complete Lysis Buffer as described above. For SDS-
PAGE, recombinant PfCyRPA, cell- or parasite lysates 
were resolved on precast 4–12 % gradient gels (NuPAGE® 
Novex 4–12 % Bis–Tris Gel, Life Technologies) with MES 
running buffer according to the manufacturer’s direc-
tions. For analyses under reducing conditions, samples 
were reduced with 50  mMf dithiothreitol (DTT) and 
heated to a temperature of 70 °C for 10 min prior to load-
ing. The proteins were electrophoretically transferred 
to nitrocellulose membrane using a dry-blotting system 
(iBlot, Life Technologies). After blocking the membrane, 
specific proteins were detected with appropriate dilutions 
of mAbs followed by HRP-conjugated goat anti-mouse 
IgG Abs (SouthernBiotech). Blots were developed using 
the ECL western blotting detection reagents (Pierce).
Immunofluorescence staining of infected erythrocytes 
and free merozoites
For indirect immunofluorescence microscopy, smears of 
infected red blood cells or free merozoites were fixed in 
60 % methanol and 40 % acetone for 2 min at −20 °C, air-
dried and blocked with 3 % BSA in PBS. Parasites were 
probed with the following antibodies: biotin-labelled 
anti-PfCyRPA mAb SB3.3b and Alexa 568-labelled 
streptavidin (Invitrogen), Alexa 488-labelled mouse 
anti-GAPDH 1.4a mAb [51]. The slides were mounted in 
mounting medium containing DAPI (ProLong Gold anti-
fade reagent with DAPI, Life Technologies). Fluorescence 
microscopy was performed on a Leica DM-5000B using a 
60× oil immersion objective lens and documented with 
a Leica DFC345FX digital camera system. Images were 
processed using Leica Application Suite V4 (Leica) and 
Adobe Photoshop® CS6.
In vitro growth inhibition assay
In vitro growth inhibition assays with P. falciparum strain 
3D7 were conducted essentially as described [52]. Each 
culture was set up in triplicate in 96-well flat-bottomed 
culture plates. The cells were analysed in a FACSscan flow 
cytometer (Becton–Dickinson) using CellQuest software. 
A total of 30,000 cells per sample were analysed. Percent 
inhibition was calculated from the mean parasitaemia of 
triplicate test and control wells as follows:
In vivo growth inhibition assay
Monoclonal antibodies were tested in the murine P. fal-
ciparum model essentially as described [32, 53]. Human 
blood (0.75 ml) was administered daily by the i.v. or i.p. 
route. Mice received a single dose of mAbs formulation 
Percent inhibition (%) =
control − test
(
control
/
100
)
by i.v. injection. The following day, mice were infected 
with 3 × 107 parasitized erythrocytes. Parasitaemia was 
monitored daily by flow cytometry over 6 days (day 4–9 
after mAb injection). To measure serum levels of admin-
istered mAbs, serum samples were taken 1 and 8  days 
after injection.
Results
Recombinant expression of PfCyRPA
For the production of correctly folded recombinant 
secreted PfCyRPA (aa. 26–362), the GPI-anchor motif 
was removed from the coding sequence of PFD1130w 
and expressed the ORF as hexa-Histidine (His-tag) fusion 
protein in the human embryonic kidney cell line Free-
Style 293-F cells. While the predicted molecular mass 
of the recombinant protein, designated G-CyRPA, was 
40.9 kDa, a discrete band of about 48 kDa was detected 
both in SDS-PAGE and Western Blot analyses with a 
PfCyRPA-specific mAb (Fig.  1a, b). When analysed for 
the presence of N-glycosylation sites (NetNGlyc 1.0 
Server) [Gupta et al. pers. comm], three asparagine resi-
dues were predicted as potential sites for N-glycosylation 
(N145, N322 and N338) in human cells. Recombinant 
G-CyRPA was then treated with PNGase F, which enzy-
matically removes N-linked carbohydrate residues from 
proteins. As expected, this treatment reduced the size of 
G-CyRPA by about 8 kDa (see Additional file 1).
The shift in molecular mass after PNGase F treatment 
suggests that G-CyRPA is indeed N-glycosylated when 
recombinantly expressed in HEK cells. Therefore, a non-
glycosylated variant of PfCyRPA, designated N-CyRPA, 
was generated by replacing the three asparagine residue 
potentially implicated in N-glycosylation with glutamine 
residues (N145Q, N322Q, N338Q). As expected, N-CyRPA 
expressed in HEK cells migrated, both in SDS-PAGE and 
western Blot analyses with a PfCyRPA-specific mAb, as a 
discrete band of about 41 kDa (Fig. 1a, b; Additional file 2).
Immunogenicity of recombinant PfCyRPA and generation 
of PfCyRPA‑specific mAbs
Mice were immunized three times with 20  µg of recom-
binant G-CyRPA or N-CyRPA emulsified in aluminium 
hydroxide containing CpG ODN as immune enhancer 
[44]. After the third immunization, PfCyRPA-specific 
serum IgG endpoint titers were determined by indirect 
ELISA. All mice raised antibody responses against recom-
binant PfCyRPA, irrespective of the immunogen’s gly-
cosylation state (P  =  0.9591, Mann-Withney test, 95  % 
confidence interval, two-tailed P value). As expected, mice 
raised also marginal antibody responses against the hexa-
His tag, as indicated by a low antibody titer against the 
hexa-His tagged irrelevant protein MUL_3720 (Fig.  2a). 
Also, all immunized mice raised immune responses 
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cross-reactive with P. falciparum endogenous PfCyRPA, 
as shown by western blot analyses on late blood-stage 
parasite lysates (Fig.  2b). Hybridoma cell lines producing 
PfCyRPA-specific mAbs were generated by fusing spleno-
cytes of immunized mice with myeloma cells. Based on 
reactivity to recombinant PfCyRPA in ELISA, a panel of 11 
anti-PfCyRPA mAbs was generated and tested for reactiv-
ity on recombinant and P. falciparum expressed PfCyRPA 
by western blot analyses. 8/11 anti-PfCyRPA mAbs stained 
the recombinant PfCyRPA band and ten of them also 
stained either strongly (mAbs SB1.6, SB2.1, SB2.3, SB3.3 
and SB3.9) or weakly (SB1.5, SB2.4, SB2.5, SB3.8 and 
SB3.8) a band of the size expected for PfCyRPA in P. fal-
ciparum schizont-stage lysate (Fig. 3; Table 1). In indirect 
immunofluorescence staining of asexual blood stage para-
sites, 9/11 mAbs were positive. mAb SB2.2 was positive in 
ELISA with recombinant PfCyRPA, but negative both in 
western blot analysis and in IFA (Table 1). With the excep-
tion of mAb SB3.8, which in ELISA was reacting only to 
recombinant G-CyRPA, no general differences in binding 
properties, between anti-PfCyRPA mAbs produced against 
glycosylated or non-glycosylated recombinant PfCyRPA, 
were observed (Table 1). In indirect immunofluorescence 
and western blotting analyses mAbs stained asexual blood 
stage parasites stage-specifically (Fig.  4; Table  1), since 
PfCyRPA is only expressed by schizonts and free mero-
zoites [32]. As expected, the generated mAbs showed 
the characteristic pattern [32] consisting of a small spot 
toward the merozoite apical pole (see Additional file 3).
Vaccine elicited anti‑PfCyRPA mAbs inhibit parasite growth 
in vitro
For the analysis of the growth inhibitory activity of mAbs 
generated against the purified recombinant PfCyRPA, 
parasites were cultured for two cycles of merozoite inva-
sion in the presence of anti-PfCyRPA mAbs at concentra-
tions of 500, 250, and 125  µg/ml. Anti-PfCyRPA mAbs 
with parasite growth inhibitory activity higher than 
40  % at the concentration of 500  µg/ml were classified 
as inhibitory and those with an inhibitory effect ranging 
between 20 and 40 %, were classified as partially inhibi-
tory. Among the four inhibitory mAbs (SB1.6, SB2.1, 
SB2.3, and SB3.3), SB1.6 showed the highest activity by 
reducing parasite growth by 64 ± 3.2 % when tested at a 
concentration of 500 µg/ml (Fig. 5; Table 1). Another four 
anti-PfCyRPA mAbs inhibited parasite growth partially, 
whereas three mAbs showed no inhibitory effect (Fig. 5; 
Table 1). All tested mAbs were produced and purified in 
the same way and results were reproducible in independ-
ent experiments and with independent mAb production 
batches (see Additional file 4).
Vaccine elicited anti‑PfCyRPA mAbs inhibit parasite growth 
in vivo
The in  vivo parasite inhibitory activity of the generated 
anti-PfCyRPA mAbs was evaluated in the P. falciparum 
SCID murine model [53] that employs non-myelode-
pleted NOD-scid IL2Rγnull mice engrafted with human 
erythrocytes. Groups of three mice received 2.5 or 0.5 mg 
of PfCyRPA-specific mAbs, either mAb SB1.6 generated 
here, or the previously described [32] invasion-inhibitory 
mAb c12, by i.v. injection. The control group received the 
same volume of PBS. Mice were infected with parasitized 
erythrocytes 1 day after the antibody transfer and para-
sitaemia of all mice was monitored for 6 days (Fig. 6). In 
the control group, parasitaemia reached 22.9 ± 1.7 % on 
day 9. Parasitaemia in mice having received 2.5 mg anti-
PfCyRPA mAbs SB1.6 or c12 increased only marginally, 
Fig. 1 Expression of recombinant PfCyRPA. Glycosylated and non-glycosylated recombinant PfCyRPA (G-CyRPA and N-CyRPA, respectively) were 
expressed as His-tagged proteins in HEK cells and purified by affinity chromatography. Proteins were analysed by denaturing/reducing gel electro-
phoresis (SDS-PAGE) and stained with Coomassie blue (a), and identified by western blot analysis with the PfCyRPA-specific mAb c12 [32] (b)
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reaching 2.2 ±  1.4 and 1.5 ±  0.6 % on day 9 after mAb 
injection, respectively. At the lower dose of 0.5 mg anti-
PfCyRPA mAbs SB1.6 or c12 inhibited parasite growth 
to 10 ±  1.6 and 12.8 ±  5.8 % parasitaemia, respectively 
(Fig.  6). Titration of administered mAbs in the serum 
of the passively immunized mice by ELISA showed that 
antibodies, although at reduced level, persisted over the 
entire study period. One day after mAb injection (2.5 mg 
dose), when mice were infected, PfCyRPA-specific mAb 
concentrations were estimated to be 295  ±  0.3 and 
389 ± 0.1 % μg/ml of serum, for SB1.6 and c12, respec-
tively. Eight days after mAb injection, at the end of the 
experiment, antibody concentrations had dropped down 
to 74  ±  0.1 and 83  ±  0.2  %  μg/ml, for SB1.6 and c12, 
respectively (see Additional file 5).
Fine specificities of anti‑PfCyRPA mAbs
The fine specificities of the generated anti-PfCyRPA 
mAbs were analysed by Ab–Ab competition ELISA on 
recombinant PfCyRPA. The in  vitro growth-inhibitory 
anti-PfCyRPA mAbs SB1.6, SB2.1, SB2.3, and SB3.3 com-
peted against each other for their antigen binding site 
(Fig. 8a). These four mAbs did neither compete with the 
partially inhibitory mAbs SB2.5 and SB3.7 nor with the 
previously described parasite inhibitory anti-PfCyRPA 
mAb c12. Additionally, the reactivity of anti-PfCyRPA 
mAbs with overlapping protein fragments of PfCyRPA 
[32] was tested by western blotting analysis (Figs. 7, 8b). 
With the exception of SB2.5, all tested anti-PfCyRPA 
mAbs reacted with fragment 26–251. All four inhibi-
tory anti-PfCyRPA mAbs SB1.6, SB2.1, SB2.3, and SB3.3 
recognized the same fragments, i.e., bound to fragment 
74–251, but not to the truncated sub-fragments 26–142, 
74–181, and 127–251, indicating that they recognize 
a conformational epitope present in fragment 74–251. 
Furthermore, the partially inhibitory mAbs SB3.7 and 
the control mAb c12 showed the same reactivity pattern. 
Based on the complementary results of both epitope clas-
sification assays, the anti-PfCyRPA mAbs was assigned to 
four distinct epitope groups (Fig. 8b, c). 
Discussion
On the basis of available genome-wide transcriptomic 
and proteomic data, Dreyer et  al. [38] have selected 
uncharacterized surface proteins, with specific expres-
sion in extracellular parasite stages, to evaluate their 
potential as blood stage vaccine candidate antigens. A 
panel of candidates was characterized (e.g., abundance, 
distribution and parasite growth inhibitory potential) 
using antigen-specific mAbs, which were generated 
exploiting a cell-based approach that utilizes antigen-
expressing living cells for mouse immunization. This 
strategy has led to the identification of PfCyRPA as prom-
ising blood-stage malaria vaccine candidate: generated 
anti-PfCyRPA mAbs showed parasite in vitro and in vivo 
growth-inhibitory activity due to inhibition of merozoite 
invasion [32]. Since antigen-loaded mammalian cells are 
Fig. 2 Anti-PfCyRPA IgG responses in outbred NMRI mice. Anti-
PfCyRPA IgG immune responses were determined 2 weeks after the 
third immunization. Mice were immunized either with glycosylated 
(G-) or non-glycosylated (N-) recombinant PfCyRPA. a Serum IgG 
endpoint titers were measured using ELISA plates coated with 
recombinant G-CyRPA. As control, serum IgG endpoint titers were 
also measured using ELISA plates coated with an unrelated hexa-His 
tagged protein (MUL_3720). Horizontal lines designate geomet-
ric means and each data point represents one animal. Data were 
processed and analysed using GraphPad Prism 6.0 (GraphPad). b 
Pre-immune (upper panel) and immune (lower panel) serum samples 
of individual mice were tested by Western-blotting analysis on P. falci-
parum 3D7 schizont-stage parasites under non-reducing conditions. 
The anti-PfCyRPA mAb c12 and the anti-GAPDH mAb 1.4a were used 
as positive control [32, 51]; the secondary antibody without primary 
antibody served as negative control
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not suitable for human immunization, here it was inves-
tigated whether growth inhibitory anti-PfCyRPA Abs 
could be raised by active immunization with adjuvanted 
purified recombinant PfCyRPA protein.
The expression of Plasmodium antigens in heterolo-
gous hosts as stable recombinant protein can be challeng-
ing. Since PfCyRPA is a cysteine-rich protein, disulfide 
bonds play an important role in its folding. Aiming at the 
Fig. 3 Western blotting analysis of anti-PfCyRPA mAbs. Anti-PfCyRPA mAbs were tested by western-blotting analysis on a recombinant G-CyRPA 
and b N-CyRPA (both sample were analysed under reducing conditions). Anti-PfCyRPA mAbs were also tested on P. falciparum 3D7 schizont-stage 
parasites under non-reducing (c) and reducing conditions (d). The anti-PfCyRPA mAb c12 and the anti-GAPDH mAb 1.4a were used as positive 
control [32, 51]; the secondary antibody without primary antibody served as negative control
Table 1 Summary of anti-PfCyRPA mAbs characterization
Anti-PfCyRPA mAbs were characterized by ELISA (+, OD value higher than control anti-6xHis mAb HIS-6/9; −, OD value ≤ control mAb), western blotting analyses (+, 
staining; −, no staining; cf. Fig. 3), immunofluorescence assays (+, staining; −, no staining), growth inhibition assays (yes, GIA ≥40 %; no, GIA ≤20 %) and categorized 
into distinct epitope groups by epitope mapping experiments (cf. Fig. 8). G-CyRPA designates recombinant glycosylated PfCyRPA whereas N-CyRPA designates non-
glycosylated recombinant PfCyRPA
mAb Immunization ELISA Western blotting analysis IFA GIA Epitope 
group
G‑CyRPA N‑CyRPA G‑CyRPA N‑CyRPA P. falc. 3D7 P. falc. 3D7 P. falc. 3D7
SB1.5 G-CyRPA + + + + + − Partial nd
SB1.6 G-CyRPA + + + + + + Yes F
SB2.1 N-CyRPA + + + + + + Yes F
SB2.2 N-CyRPA + + − − − − Partial nd
SB2.3 N-CyRPA + + + + + + Yes F
SB2.4 N-CyRPA + + − − + + No nd
SB2.5 N-CyRPA + + + + + + Partial A
SB3.3 G-CyRPA + + + + + + Yes F
SB3.7 G-CyRPA + + + + + + Partial B
SB3.8 G-CyRPA + − − − + + No nd
SB3.9 G-CyRPA + + + + + + No E
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Fig. 4 Stage specific expression of PfCyRPA in late asexual blood stage parasites. a Indirect immunofluorescence staining of synchronized asexual 
blood stage parasites showed stage specific expression of PfCyRPA in schizont stages and free merozoites. Methanol/acetone fixed P. falciparum 
3D7 parasites were probed with the anti-GAPDH mAb (green) and the anti-PfCyRPA mAb SB3.3 (red) as representative example. Nuclei were stained 
with DAPI (blue). Exposure times were identical for all pictures of the same channel. b Western blot analysis with lysates of tightly synchronized P. 
falciparum 3D7 blood-stage parasites with anti-PfCyRPA mAb SB1.6 (upper panel). The blot was probed for equal loading with an anti-GAPDH 1.4a 
mAb (lower panel). 4, 12, 20, 28, 36, 44 h post-invasion; M free merozoites
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production of a properly folded recombinant protein, a 
eukaryotic rather than a prokaryotic expression system 
was used. Since PfCyRPA was successfully expressed 
in a native conformation on the surface of HEK cells 
and raised parasites-cross reactive mAbs [32], the same 
mammalian expression platform was exploited for the 
production of secreted PfCyRPA. For this purpose, the 
expression plasmid coding for PfCyRPA was modified to 
produce the secreted version of the protein by remov-
ing the sequence coding for the transmembrane domain 
artificially used to display the protein on the cell surface. 
PfCyRPA was expressed and secreted into the cultivation 
medium in good quality and quantity (ca.18  mg/l), and 
the glycosylated recombinant protein was easily purified 
via the hexa-His tag. Since the protein glycosylation sta-
tus may influence immunogenicity, a non-glycosylated 
version of PfCyRPA was also produced, but no marked 
difference between the two proteins could be found with 
respect to their immunogenicity. To dissect and charac-
terize the properties of the elicited anti-PfCyRPA antibody 
response, mice immunized with either the glycosylated or 
the non-glycosylated recombinant protein were employed 
to generate a panel of eleven IgG mAbs reactive with 
recombinant PfCyRPA in ELISA. Nine of the generated 
mAbs were cross-reacting in indirect immunofluores-
cence analysis with P. falciparum asexual blood stage 
parasites, yielding a dotted staining pattern characteristic 
for PfCyRPA and ten of them stained a band of the size 
expected for PfCyRPA in western blotting analysis with 
P. falciparum schizont stage lysate. Four mAbs showed 
strong and another four partial parasite blood stage 
in vitro growth inhibitory activity. The parasite inhibitory 
activity of mAb SB1.6 showing the strongest in vitro activ-
ity was comparable to that of the previously described 
anti-PfCyRPA mAb c12 which was produced after immu-
nization with mammalian cells expressing recombinant 
PfCyRPA on their cell surface [32]. The strongly growth 
inhibitory mAbs c12 and SB1.6 do not compete for anti-
gen binding (Fig.  8), confirming that PfCyRPA harbours 
more than one target epitope for inhibitory antibodies, as 
already suggested by Dreyer et al. [32].
Structural analyses with antigen–antibody complexes 
are required to gain deeper insight into the targets and 
mode of action of these antibodies. Since orthologs of 
PfCyRPA are only present in the human malaria parasite 
P. vivax and the primate pathogens P. knowlesi, P. cyn-
omolgi, and P. reichenowi [54–56], but are absent in Plas-
modium species infecting rodents, conventional mouse 
Fig. 5 Vaccine elicited anti-PfCyRPA mAbs inhibit parasite growth in vitro. Synchronized P. falciparum 3D7 parasites were cultivated for 96 h in 
the presence of anti-PfCyRPA mAbs. The percentage of growth inhibition was calculated against the parasitaemia of PBS control wells. Each bar 
represents the mean of a triplicate experiment, and error bars indicate the SD. Anti-PfCyRPA mAbs SB1.6, SB2.3, SB2.1 and SB3.3 are growth inhibitory 
mAbs, mAb SB1.5 is shown as an example for a partially inhibitory mAb, and mAb SB3.8 as an example for a non-inhibitory mAb. The anti-cortisol 
mAb CORTI-4/16 was used as negative control and the anti-PfCyRPA mAb c12, which was produced after immunization with mammalian cells 
expressing recombinant PfCyRPA on their cell surface, as positive control [32]
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models with rodent parasites cannot be used to evaluate 
the in  vivo growth inhibitory activity of anti-PfCyRPA 
mAbs. Therefore, passive immunization experiments 
were performed exploiting an innovative P. falciparum 
SCID mouse model [32, 53].
Non myelo-depleted NOD-scid IL2Rγnull mice, 
engrafted with human erythrocytes to allow the growth 
of P. falciparum, received a single dose of anti-PfCyRPA 
mAbs via the i.v. route and were infected with P. falcipa-
rum 3D7 parasites on the subsequent day. In mice receiv-
ing SB1.6 mAb, a strong, dose-dependent parasite growth 
inhibitory effect was observed, reducing parasite’s growth 
by about 90 % (2.5 mg dose). The concentration of mAb 
SB1.6 in the circulation of the passively immunized mice 
which received the higher dose, was estimated to be 300 
and 80  μg/ml 1 and 8  days after injection, respectively. 
Since SCID mice lack the adaptive immune system and 
have deficiencies in the innate immune system [57, 58], 
the injected mAbs were the only circulating IgG, and this 
may enhance their clearance from the circulation. How-
ever, the measured serum concentration of PfCyRPA-
specific antibody fall in the range of specific Abs that can 
be induced by appropriate vaccine formulations [8, 37]. 
In this context, it should also be taken into account that 
immunizations with recombinant PfCyRPA (both anti-
gen-loaded cells and adjuvanted purified proteins) gen-
erated anti-PfCyRPA mAbs with different fine specificity 
[32].
Hence, stronger inhibitory activities may be achieved 
in the context of active immunizations, where Abs spe-
cific for more than one inhibitory epitope are induced, 
and lower titers of total PfCyRPA-specific Abs may be 
required to confer substantial protection. As already 
described [32], anti-PfCyRPA mAbs reduce, but do not 
completely block, parasite growth by inhibiting a crucial 
invasion pathway of erythrocytes by merozoites.
Invasion of host erythrocytes is a complex and criti-
cal step in the life cycle of malaria parasites, and P. 
Fig. 6 Vaccine elicited anti-PfCyRPA mAbs inhibit parasite growth 
in vivo. NOD-scid IL2Rγnull mice received purified anti-PfCyRPA mAbs 
by i.v. injection. Mice were then infected with P. falciparum 3D7 and 
parasitaemia was monitored over 6 days. Values are the mean parasi-
taemia in human erythrocytes in peripheral blood of three mice per 
group. Error bars indicate the SD. PBS was used as negative control, 
the anti-PfCyRPA mAb c12 as positive control [32]
Fig. 7 Reactivity pattern of anti-PfCyRPA mAbs with recombinant PfCyRPA fragments. Anti-PfCyRPA mAbs were tested by western blot analysis on 
lysates of HEK cells expressing recombinant PfCyRPA fragments. A lysate HEK cells transfected with empty plasmids served as negative control. Both 
samples were analysed under reducing conditions. a Reactivity pattern of anti-6xHis mAb HIS-6/9 as positive control for expression. b Reactivity 
pattern of anti-PfCyRPA mAb SB 3.7 as a representative example
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falciparum has evolved an abundance of antigenically 
diverse, and probably functionally redundant, mero-
zoite surface proteins to facilitate parasite escape from 
host immune detection and ensure invasion via multi-
ple pathways [59, 60]. In this respect, marginal sequence 
polymorphisms and limited natural immunogenicity of 
PfCyRPA [32] suggest a critical function of PfCyRPA in 
erythrocytes invasion, which prevents sequence variation 
and accessibility to the immune system in the natural con-
text. PfCyRPA has been recently identified as the anchor 
protein that tethers PfRH5, and its interacting partner 
PfRipr, to the surface of merozoites [33]. PfRH5 has been 
shown to play a key role in the attachment of merozoites 
to the erythrocyte surface via the interaction with the 
host receptor basigin [61, 62]. Interestingly, PfCyRPA 
and PfRH5 genes are located in close proximity in the 
genome, have no substantial sequence polymorphisms, 
have demonstrated poor natural immunogenicity, and 
elicit potent and strain-transcending growth-inhibitory 
parasite antibodies [32, 34]. Anti-PfCyRPA mAb concen-
trations required for substantial growth inhibition in GIA 
were higher than those reported for anti-basigin (1  μg/
ml) and anti-PfRH5 (15 μg/ml) mAbs, respectively [36]. 
This may be in part related to different assay formats, but 
also to other factors, such as accessibility of the antigens 
and kinetic and thermodynamic features of mAb bind-
ing. Reddy et al. [33] also reported a synergistic in vitro 
inhibitory activity for the combination of polyclonal anti-
PfCyRPA and anti-PfRH5 antibodies. Targeting simul-
taneously PfCyRPA and PfRH5 seems to hinder parasite 
invasion more effectively than when blocking only one 
component of the multiprotein invasion complex. Taken 
together, these findings suggest that additional investiga-
tion are needed for an in depth characterization of the 
invasion complex, and make both PfCyRPA and PfRH5 
appealing candidates for the development of new anti-
malarial vaccine strategies.
Conclusions
A vaccine formulation composed of adjuvanted recom-
binantly expressed PfCyRPA has been shown to elicit in 
mice high titers of antibodies that inhibit both in  vitro 
and in  vivo P. falciparum asexual blood stage parasite 
growth. These findings qualify PfCyRPA, a highly con-
served and poorly immunogenic merozoite protein, as 
highly suitable candidate antigen for inclusion into a 
strain-transcending, multivalent malaria subunit vaccine.
Fig. 8 Epitope specificities of anti-PfCyRPA mAbs. a Anti-PfCyRPA 
mAbs were tested in an Ab–Ab competition ELISA. x Ab competi-
tion (signal reduction higher than 30 %; measured values: min. 34 %, 
max. 91 % reduction), − no Ab competition (measured values: min. 
−10 %, max. 21 % reduction. b Reactivity of anti-PfCyRPA mAbs with 
recombinant PfCyRPA fragments were investigated by western blot-
ting analyses performed on lysates of HEK cells expressing recombi-
nant PfCyRPA fragments. x staining, − no staining (an example of the 
reactivity pattern is reported in Fig. 7b). c Anti-PfCyRPA mAbs were 
assigned to different epitope groups according to the results from 
the Ab–Ab competition ELISA and the epitope mapping experiment. 
d P. falciparum in vitro growth inhibition activity of mAbs
Additional files
Additional file 1. PNGase F treatment of recombinant G-CyRPA. 1 mg/ml 
of native (second lane) or reduced with 50mMf DTT (third lane) G-CyRPA 
was subjected for 16 h at room temperature to PNGase F at a final 
concentration of 0.05 mg/ml, and analysed by reducing SDS-PAGE (1 μg 
protein per lane). Lane 1: untreated G-CyRPA; lane 4: PNGase F.
Additional file 2. Recognition of N-CyRPA by PfCyRPA- and 6xHis-specific 
mAbs. Reducing (R) and non-reducing (N) SDS-PAGE of non-glycosylated 
PfCyRPA (N-CyRPA) detected by Coomassie-staining (blue) and Western 
blotting with anti-PfCyRPA mAb c12 and anti-6xHis mAb HIS-6/9 (black). 
Analyses under non-reducing conditions revealed both a monomeric and 
a dimeric form of PfCyRPA.
Additional file 3. Localization of PfCyRPA in late asexual blood stage 
parasites. Indirect immunofluorescence staining of P. falciparum 3D7 schi-
zont stages. Methanol/acetone fixed parasites were co-immunostained 
with mAbs against PfCyRPA (red) and AMA-1 (marker for micronemes), 
RAP-1 (marker for rhoptry bulbs), MSP-1 or MSP-5 (marker for merozoite’s 
surface) (green). Parasites were probed with the following primary or 
secondary antibodies: biotin-labeled anti-PfCyRPA mAb SB3.3b, Alexa 
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